Overview
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.
Eligibility
Key Inclusion Criteria:
- Subjects ≥18 and <75 years of age
- Presence of moderate to severe dry eye disease (DED) in at least one eye
Key Exclusion Criteria:
- Presently using prescription eyedrops, except those used for dry eye disease, which must be discontinued 4 weeks prior
- Use of over-the-counter (OTC) eyedrops except for lubricant eyedrops or artificial tears, within 1 week prior to initiation of study drug dosing
- History or evidence of ocular infection within the previous 30 days
- Blepharitis or meibomian gland disease requiring the use of either topical or systemic antibiotics within 2 months
- Allergic conjunctivitis requiring treatment within 30 days
- Unable to discontinue contact lens wear for 2 weeks prior and for the duration of the study